Patients currently taking metformin will be eligible
Patients may not be taking metformin for a reason other than study participation
Patients must not receive metformin for at least  days prior to enrollment and for the duration of study treatment
Subjects may have diabetes mellitus but must not be taking metformin
Known hypersensitivity to metformin
Subjects currently treated with metformin and/or bicalutamide or who have been treated with metformin and/or bicalutamide in the past  months
Prior or current use of metformin within the past  months
Subjects may have diabetes mellitus but must not be taking metformin or have previously taken metformin within previous year
Subjects who are pregnant or breastfeeding, or may become pregnant during metformin and doxycycline administration
Subjects on metformin or doxycycline for any reason during the preceding  weeks
Diabetic subjects that are managed by taking metformin or insulin
Patient with prior allergic reaction to metformin, doxycycline, or any other tetracycline antibiotic in the past
Patient is on medications that are contraindicated with metformin or doxycycline under current Food and Drug Administration (FDA) recommendations; the following is a list of medications identified as class D (consider therapy modification) when treatment with metformin or doxycycline is considered:\r\n* Class D:\r\n** Bismuth Subsalicylate\r\n** Cimetidine\r\n** Iodinated contrast agents\r\n** Somatropin
Both arms: patients should not have received metformin within  months prior to registration\r\n* Arm B: patients who were on metformin while on PD-/PD-L inhibitors are not eligible
Patients must not have any of the following contraindications to metformin:\r\n* Hypersensitivity to metformin or any component of the formulation\r\n* Kidney dysfunction or abnormal creatinine (Cr <  ng/mL) from any cause\r\n* Acute or metabolic acidosis
Patients must be at least  half-lives beyond previous treatment with metformin and currently not taking metformin
History of hypersensitivity to TAK- or metformin
Subjects who are pregnant or breastfeeding or may become pregnant during metformin and doxycycline administration
Subjects on metformin or doxycycline for any reason during the preceding  weeks
Diabetic subjects are eligible if they are not taking metformin or insulin
Prior allergic reaction to metformin, doxycycline, or any other tetracycline antibiotic in the past
Patient is on medications that are contraindicated with metformin or doxycycline under current Food and Drug Administration (FDA) recommendations; the following is a list of medications identified as class D (consider therapy modification) when treatment with metformin or doxycycline is considered\r\n* Class D \r\n** Bismuth Subsalicylate\r\n** Cimetidine\r\n** Iodinated contrast agents\r\n** Somatropin
Known sulfonylurea treatment within  days prior to registration; sulfonylureas include glyburide/glibenclamide (Diabeta, Glynase); glyburide plus metformin (Glucovance); glimepiride (Amaryl); repaglinide (Prandin); nateglinide (Starlix); glipizide (Glucotrol, GlibeneseR, MinodiabR); gliclazide (DiamicronR); tolbutamide (Orinase, Tolinase); and glibornuride (Glutril)
Patients who are currently taking metformin; prior metformin use is allowed if last dose was  months previous to this trial
Currently taking metformin, sulfonyureas, thiazolidenediones or insulin for any reason
History of hypersensitivity to temsirolimus or metformin
Subjects with known diabetes and those taking metformin, sulfonylureas, thiazolidinediones or insulin for any reason
Patients taking metformin or digoxin
Patients currently using metformin (metformin hydrochloride), other oral hypoglycemic agents or insulin
Patients must NOT be taking metformin or have been on metformin in the past  months
Diabetic patients who are on metformin are eligible as long as they have been on metformin for less than  months (estimated  months or less duration of metformin therapy from start of metformin to enrollment on study)
Current use of metformin for more than  months prior to enrollment on study
Patients who received aspirin or metformin within the past  days
Patients taking medications with known interactions with metformin or aspirin
Currently taking metformin, sulfonylureas, thiazolidinediones, or insulin for any reason
Have no contraindications to short-term metformin therapy
Need to be able to undergo metformin treatment for a duration of  weeks (+/-  days) prior to repeat endometrial biopsy
Are currently taking metformin or have taken metformin in the past  months or have a history of an allergic reaction or intolerance at any time to metformin
Are taking a drug that may significantly interact or influence the metabolism of metformin
Prior metformin treatment OR EGFR targeted therapy
Patients taking Metformin for any reason within  days of enrollment to the study
Subjects on metformin for any reason during the preceding  weeks
Diabetic subjects are eligible if they are not taking metformin, insulin or sulfonylureas
Currently taking metformin, sulfonylureas, thiazolidinedione, insulin, or other antidiabetic drugs for any reason
Patients already receiving metformin or anti-diabetic medications are INELIGIBLE
Metformin use in the last  months
A known hypersensitivity to metformin
Known intolerance to doxorubicin, metformin, or vincristine
Patients who have a need to continue hydroxyurea while on study\r\n* Please note: patients may continue on hydroxyurea only until the first dose of metformin is to be given
Known hypersensitivity to metformin or statins
Patients currently treated with metformin or a statin or who have been treated with metformin or a statin in the past  months are ineligible for this study
Subjects on metformin for any reason during the preceding  weeks
Diabetic subjects are eligible if they are not taking metformin, insulin or sulfonylureas
All medications other than those that may cause myelosuppression are permitted except those that are contraindicated with metformin under current Food and Drug Administration (FDA) recommendations
Current metformin therapy
Subjects who are pregnant or may become pregnant during metformin administration; pregnancy testing will be done in conjunction with preradiation protocols
Subjects on metformin for any reason during the preceding  weeks
Diabetic subjects are eligible if they are not taking metformin or insulin
All medications are permitted except those that are contraindicated with metformin under current Food and Drug Administration (FDA) recommendations
Patients currently receiving or scheduled to receive a chemotherapy infusion other than adriamycin/cyclophosphamide prior to initiation of the metformin adaptation phase are not eligible; patients who are receiving adriamycin/cyclophosphamide must be scheduled to be at least  days post-chemotherapy infusion prior to initiation of the metformin adaptation phase in order to be eligible
Patients who are currently using metformin (eg, Fortamet, Glucophage, Glucophage XR, Glumetza, Riomet)
Contraindication to metformin prevention such as acute hypersensitivity or allergic reaction to metformin
Women who have taken metformin within the past  days
Currently taking medication that may impact weight (e.g., Synthroid, metformin)
Current or prior regular use of metformin within the past  months
Current use of metformin or other anti-diabetic agents, or hypersensitivity or allergy to metformin
Participants may not be using metformin, cimetidine (Tagamet), furosemide (Lasix), nifedipine (Cardizem), or any other drug contraindicated for use with metformin
No current treatment with metformin, sulfonylureas, thiazolidinediones or insulin for any reason
Prior treatment with metformin
Known allergy to metformin or other biguanide (Proguanil)
Participants who are taking metformin at the time of the exam are excluded
Taking metformin (example: Glucophage, Glucovance, Avandamet, Metaglip)
Currently taking Glucophage or Glucovance (metformin)
NORMAL VOLUNTEERS: Be taking metformin, aminoglycosides, other nephrotoxic medications, or daily use of NSAIDs
Patients with type  diabetes mellitus (TDM) being treated with metformin (any dose) for a clinical indication at the time of study enrollment are eligible, and will continue metformin treatment as clinically indicated during the presurgical study period. Their dose of metformin will NOT be changed
Patients not on metformin at the time of study entry must be willing to take metformin extended release (Glucophage XR,  mg QD for  days, then  mg BID for - days) for a total of - days prior to surgery\r\n* Patients do not require a diagnosis of diabetes to be enrolled in the study
All patients must be willing to keep a drug diary indicating the dates and times of metformin administration
History of diabetes that is currently being treated without metformin
Patients who, at the time of study entry, are not taking metformin for a clinical indication, and who will need a radiographic analysis with an iodinated contrast agent during the metformin study treatment period
This criterion does not apply to patients taking clinically indicated metformin at the time of study entry
Known hypersensitivity to metformin
Must have been off metformin for at least  weeks prior to starting IFN gamma
Participants who are already on treatment with metformin, except when metformin can be held for  weeks prior to the start of the study
Diabetic patients are eligible but will be excluded if they are taking metformin, insulin or sulfonilureas
